Elon Musk’s Neuralink has emerged at the forefront of brain-computer interface (BCI) technology, promising to enable individuals with paralysis to control computers and other devices through thought alone. However, the path to realizing this groundbreaking technology has not been without its complications. As Neuralink forges ahead, receiving FDA clearance to implant its BCI in a second patient, it also contends with the challenges that arose from its first human implant.
In a recent update, it was revealed that about 85% of the tiny wires in the first patient, Noland Arbaugh’s Neuralink implant, had become detached. Arbaugh, who had the coin-sized N1 BCI implanted into his motor cortex, experienced this detachment which led to a significant reduction in the number of functional electrodes. Despite these setbacks, Neuralink managed to remedy performance issues through an over-the-air software update, enhancing the implant’s functionality.
Neuralink’s proposed solution to the electrode retraction issue involves embedding the threads deeper within the brain tissue. This approach, while potentially resolving one issue, raises concerns regarding the risk of further complications, such as damage to brain tissue in the event of thread dislodgement or necessary removal of the device.
The company’s response to these challenges has been multifaceted. When the implant threads began retracting from Arbaugh’s brain, resulting in a net decrease in effective electrodes and reduced data streaming rates, Neuralink made modifications to “the recording algorithm” to become “more sensitive to neural population signals.” These changes, according to Neuralink, led to “a rapid and sustained improvement in bits-per-second (BPS),” which reportedly exceeded Arbaugh’s initial performance.
Despite these advances, Neuralink’s approach has not been without criticism. The revelation that a substantial number of electrodes are no longer functional is a poignant reminder of the unpredictable nature of pioneering medical devices. Yet, the willingness to seek FDA approval for a second patient, which has been granted, indicates a confidence in their capability to overcome these obstacles.
The FDA’s green light for a second implant comes with the company’s assurance that they have learned from the initial complications. More than 1,000 individuals have registered their interest in participating in Neuralink’s PRIME Study. This keen public interest underscores the potential impact of such technology on the lives of people with severe mobility impairments.
As the company aims to perform additional nine implant surgeries by the end of the year, Neuralink continues to refine its technology. The company’s blog posts reveal aspirations beyond cursor control, extending to “robotic arms, wheelchairs, and other technologies that may help increase independence for people living with quadriplegia.”
Relevant articles:
– 85% of Neuralink implant wires are already detached, says patient, popsci.com, 05/22/2024
– Neuralink Nabs FDA Green Light to Implant in Second Patient, MD+DI, 05/20/2024
– Neuralink Admits That Implant’s Threads Have Retracted From First Patient’s Brain, Possibly Due to Air in Skull, Yahoo News Australia, 05/20/2024
– Neuralink Receives FDA Clearance for Second Brain Implant Procedure, Tech Times, 05/21/2024
– Elon Musk’s Neuralink to Implant Brain Chip in Second Patient, News9 LIVE, 05/20/2024
Glad you enjoyed above story, be sure to follow TrendyDigests on Microsoft Start.